ImunoBran® MGN-3

ImunoBran® = BioBran® = Bi.Bran®


Want to know more about the immune system?

Immune system 

Overview

ImunoBran® MGN-3 was first developed in Japan in 1992 by Hiroaki Maeda, Director of Research and Development of Daiwa Pharmaceutical Co., Ltd, in Tokyo. Maeda's area of interest is in finding natural phytonutrient solutions for both human health and agriculture, and in the late 1980s, he turned his attention to polysaccharides, which have been known to have been known to strengthen immune response, and developed the immune system supplement, AHCC®.

After moving to Daiwa Pharmaceutical, headed by Yasuo Ninomiya, Maeda developed a new complex of short chain polysaccharides (primarily arabinoxylan and other hemicelluloses) which he gave the generic name MGN-3 after the initials of its developers - M-Maeda, G-Ghoneum, N-Ninomiya and "3" because it was a third generation product. (Mamdooh Ghoneum, Professor of Immunology at Drew University of Medicine and Science in Los Angeles, did much of the immunological research with the product.) Daiwa subsequently marketed this MGN-3 complex under the brand name ImunoBran® MGN-3.​

ImunoBran® MGN-3 Evidence Based Immunomodulator

A non-toxic dietary supplement with arabinoxylan (or functional food), produced by breaking down rice bran fibre using enzymes from the Shiitake mushroom. It has been clinically proven to significantly improve weakened immune systems, making it a suitable dietary supplement for people with weakened immunity.  (Une étude narrative est disponible ICI : Propriétés bénéfiques pour la santé et applications cliniques de l'arabinoxylane de son de riz modifié par l'enzyme du champignon Shiitake

What is ImunoBran® MGN-3 arabinoxylan compound?

It has been well documented, for many years, that certain large polysaccharide molecules - complex carbohydrates such as plant fibre - can stimulate the immune system. Fibre in general has also been linked in research to the lowering of cholesterol, improved sugar metabolism and the reduction of intestinal toxicity; rice bran has anti-viral properties whereas certain mushroom fibre has been shown to enhance immune response. Unfortunately, plant fibres are mostly indigestible, and so these immune enhancing benefits remain mostly unrealized as the fibre passes through and out the body. However, if these very long polysaccharide molecules (specifically from rice bran) are broken up into much smaller components, called hemicelluloses - of which the most powerful are the arabinoxylan compounds - these benefits were not only greatly magnified, but they could be directly affect the body's immune system because the fibre now had a small enough molecular weight to be absorbed undigested through the small intestine into the blood system.

The leading manufacturer of this type of hemicellulose food supplement is Daiwa Pharmaceutical in Japan, which has a unique and patented process in which rice bran is broken down (partially hydrolyzed) using Shitake mushroom enzymes (lentius edodes mycelia extract) to make a unique and natural blend of hemicelluloses, the principal ingredient of which is the arabinoxylan compound or b-1, 4 xylophyronase hemicellulose. (Although Shitake mushroom enzymes are used in the manufacture, there is no measurable mushroom content in the end product and so most of those with mushroom intolerances have no reaction to it.) The diagram below shows how the basic unit or segment of the fibre has been broken down or "pruned" to produce, in this case, the hemicellulose called arabinoxylan.

                                                                                                                 


The resulting blend of hemicellulose compounds from this process was generically called ImunoBran® MGN-3 - or just ImunoBran® MGN-3 for short. (Much of the research refers to it as MGN-3 which is the generic manufacturers name, although another generic name used is Modified Rice Bran - MRB). It is also referred to as ImunoBran® MGN-3 arabinoxylan compound because the arabinoxylan is one of its main components. As a blend of natural compounds (hemicelluloses), ImunoBran® MGN-3 consists of an array of short chain polysaccharides, which makes it much easier for the body to assimilate than single component substances (such as conventional drugs). This natural array of ingredients is also thought to be a reason for its non-toxicity and lack of unwanted side effects.

The Immune System

The immune system is the collective army of a trillion white blood cells, the bone marrow, antibodies, cytokines and the thymus gland that help to identify and destroy the millions of microbes (bacteria, viruses, parasites, fungi) that penetrate our bodies every day, and the thousands of our own cells that have become genetically abnormal or cancerous. In fact, the immune system is considered every bit as complex as our nervous system, and is not only able to produce a matching antibody for every one of the millions of different infective agents, but is able to remember how to produce these decades later.


What is its effect on the body?

ImunoBran® MGN-3 arabinoxylan compound can stimulate a weak immune system more powerfully and safely than any other agent, natural or synthetic. Although nobody yet knows the exact mechanism, it appears to be able to do this by increasing the body's production of natural cytokynes - substances such as interferons, interleukins and tumour necrosis factors, which not only help destroy rogue cells and viruses directly, but kick-start the immune system by increase the activity of the lymphocytes - B cells, T cells and especially NK (natural killer) cells. B cells focus on producing antibodies whilst the T and NK cells wander through the body directly destroying virally or bacterially infected cells, and cells that have turned cancerous. (In its lifetime, a single NK cell can kill as many as 27 cancer cells, sticking to them and then injecting lethal chemical granules that can destroy the abnormal cell in less than 5 minutes.)

When the body is stressed or in a diseased state, the immune system can become overloaded and the activity of these protector cells becomes sluggish. This is often compounded by medical treatment - such as chemotherapy in the case of cancer - which further depresses the immune system. A weak immune system is less able to prevent cancer cells and infections from taking hold and spreading in the body.

When it comes to disease prevention and treatment, it is therefore extremely important to optimise the functioning of the immune system, and above all the activity of NK cells, which make up 15% of white blood cells and are considered to be the 'elite units' of the system. Each increase in their activity potentially increases the chances and speed of health recovery. Research into immunomodulators therefore focuses on this single parameter - NK cell activity - which is easily measurable and gives us a good picture of the overall strength of the immune system. Most of the studies with ImunoBran® MGN-3 wholesale included the control of NK cell activity, with ImunoBran® MGN-3 shown to be able to increase slowed NK cell activity by 300% and more. ImunoBran® MGN-3 acts in the same way with regard to the activity of other immune system factors such as TNF (tumour necrosis factor). What's more, this effect is achieved without any accompanying toxicity or undesirable side-effects (unlike the synthetic cytokines currently used by oncologists where, as in the case of interleukin-2, extreme toxicity can develop).

A graph showing the increase in activity of NK cells with just two weeks on ImunoBran® MGN-3 supplementation. This activity can be scientifically measured by placing blood from a patient into a vial of live cancer cells, and then using a radioactive marker to measure, after a four hour period, the percentage of these cells destroyed by the bloods NK cells. Although intake was stopped after this two week period for this experiment, you can see from the graph that the NK activity is still well above the control level a few weeks later.

                                                                                                                                         

Research has also shown that, provided ImunoBran® MGN-3 is regularly included in the diet, this stimulation of the immune system need not decrease over time. This lack of a tail-off (or hyporesponsiveness) with prolonged use is extremely unusual for immunomodulatory substances and means that ImunoBran® MGN-3 is always effective, even with prolonged use. NK activity usually peaks around 1 or 2 months after being on a high dose, after which it can be maintained with a smaller maintenance does. The speed at which this peak is reached depends on the amount taken each day.

This ability to enhance the immune system and reduce inflammation means that ImunoBran® MGN-3 is an important food supplement for a variety of situations. (Please note that the majority of research has been conducted in relation to cancer, and that more research needs to be done on viral infections, bacterial infections and diabetes.)

​You can find more information on the following points in our published scientific articles and clinical studies. 

As a daily food supplement  - For those that are unwell, ImunoBran® MGN-3 can help speed up recovery by increasing immune function.



Our studies also show the effect of ImmunoBran on people in good health and an improvement in their quality of life.

The effects of ImunoBran/BioBran/MGN-3, an arabinoxylan rice bran, on health-related quality of life in healthy elderly people: a randomised, double-blind, placebo-controlled clinical trial

Download the document HERE


Objective: The world's elderly population is growing rapidly and there is a growing need for measures to combat age-related decline in physical, mental and cognitive function and to improve health-related quality of life (HRQOL). Biobran/MGN-3, an arabinoxylan rice bran, has already been reported to improve quality of life in cancer patients. The aim of the present study was to examine the effect of low-dose Biobran/MGN-3 supplementation on QoL in a healthy elderly population. Methods Sixty apparently healthy subjects, 40 men and 20 women, aged over 56 years, were recruited and randomised to receive either placebo or Biobran/MGN-3 (250 mg/day for 3 months). The participants did not take any vitamins or medication during the study, and their state of health was closely monitored. HRQoL was assessed at baseline and at the end of the study using the previously validated Arabic version of the SF-12v2 questionnaire. Results For all HRQOL domains measured, there was no statistically significant difference in baseline scores between the two groups. Compared with baseline and placebo-treated subjects, Biobran/MGN-3 supplementation significantly improved the levels of the physical and mental component summary scores, as well as the scores of the role-physical, bodily pain, vitality and social functioning subdomains. Conclusion These results show that Biobran/MGN-3 is a promising psychoneuroimmune modulator that could improve HRQoL in healthy older adults.


ImunoBran/Biobran/MGN-3, an arabinoxylan rice bran, improves NK cell activity in geriatric subjects: Randomised, double-blind, placebo-controlled clinical trial          

​Download the document HERE

Objective: Ageing is associated with a decline in natural killer (NK) and natural killer T (NKT) cell function, which may contribute to increased susceptibility to malignancies and infections. A preliminary study was conducted to investigate the hypothesis that rice bran arabinoxylan (Biobran/MGN-3), a denatured hemicellulose with known immunomodulatory activity, could counteract this decline in NK/NKT cell activity in the elderly. A total of 12 healthy geriatric subjects, of both sexes and aged over 56, took part in a randomised, double-blind, placebo-controlled clinical trial. Six subjects served as controls and six others ingested Biobran/MGN-3 (500 mg/day) for 30 days. The effect of Biobran/MGN-3 supplementation on NK/NKT cell activity was assessed using the degranulation test. All subjects in the study were monitored for the occurrence of unintended side effects. In addition, the pharmacological effects of Biobran/MGN-3 on blood cell components and on liver and kidney function were also assessed. The results showed that Biobran/MGN-3 had no effect on the total percentage of NK cells, but did increase the cytotoxic activity of induced differentiation group 107a expression in NK cells, compared with baseline and placebo (P<0.05). In addition, no side effects were observed, indicating that Biobran/MGN-3 supplementation is safe at the dosage used and for the duration of administration. A number of additional beneficial effects were observed, including an improvement in mean corpuscular volume and a reduction in levels of the liver enzyme aspartate aminotransferase, suggesting an improvement in liver function. It was concluded that Biobran/MGN-3 induces a significant increase in NK activity which may enhance resistance to viral infections and cancers in the geriatric population.


Cancer 

ImunoBran® has the largest number of clinical trials and scientific articles on cancer. As you can read, ImunoBran has been shown to improve the quality of life of patients undergoing chemotherapy or radiotherapy thanks to its ability to reduce the side effects of the drugs used in these types of treatment (often by reducing nausea and hair loss). ImunoBran food supplement has shown positive results in blood cancers such as multiple myeloma; interesting results have also been obtained in ovarian cancer, breast cancer, etc. (see the clinical research section for other study results). It is important to stress that ImunoBran® is not a cure for cancer, but rather a useful dietary supplement against cancer, always under the supervision of a qualified doctor. When correctly dosed, the volume of cancerous tumours in the body can be considerably reduced (this is known as the demolition process), and ImunoBran® MGN-3 can help the immune system to control the rest (most research into the effects of the arabinoxylan contained in ImunoBran® MGN-3 on cancer has been carried out in the context of the concomitant application of conventional treatments).

Here is a selection of clinical studies:

Can the activation of molecular pattern recognition receptors caused by the synergistic effect of plant immunomodulators improve the efficacy of oncological treatment? Case study of a patient suffering from sarcoma of the uterus and ovary.

​Download the document HERE

Background: A growing body of evidence supports the hypothesis that, like microbes, various plant extracts may also contain pathogen-associated molecular pattern (PAMP)-like structures that can activate type 1 cellular functions of the innate immune system. Given that they are important for tumour defence and that chemical production of PAMP structures is difficult to achieve, plant extracts standardised according to their PAMP structures could prove promising for future anti-tumour therapies. Method: The synergistic effect of two standardised plant immunomodulators was monitored by haemocytological measurement of peripheral Natural Killer (NK) cell levels. Suboptimal doses of istletoe lectins (ML) and Arabinoxylan in MGN-3 were compared using healthy volunteers. Results: 24 hours after a sub-optimal dose (15 mg/kg) of Arabinoxylan in MGN-3, a mean (+/-SEM) increase in NK levels was 46.4 (+/-36) % and 24 hours after a sub-optimal injection (0.45 ng/kg) of ML, an increase of 36 (+/-13) % was found. If these sub-optimal doses of arabinoxylan and ML were administered together, a highly significant increase (293 +/-41%) was established, indicating a significant synergy between the two (p<0.001). A patient with sarcoma of the uterus and ovary could not tolerate CYVADIC chemotherapy. After combination with ML and Arabinoxylan using optimal doses of 0.75 ng/kg and 45 mg/kg respectively, she received six cycles of CYVADIC and subsequently only immunotherapy. She remained tumour-free for the next five years. Conclusion: The combination of standardised plant extracts with PAMP-type structures seems to open up new prospects in supportive therapy for metastatic tumours. Further research is required.


Can a standardised, evidence-based plant immunomodulator (composed of rice bran arabinoxylan) synergistically enhance the effects of gemcitabine? Case study of a patient with ductal carcinoma of the pancreas. 

​Download the document HERE

Background: Pancreatic ductal carcinoma is the leading cause of cancer mortality. Gemcitabine combined with nab-Paclitaxel as standard first-line treatment leads to an improvement in clinical parameters, but this is only transient. Immunological observations suggest that in the background of this rapid resistance, tumour-induced dysregulation of the immune balance may also play a role. Tumour-induced innate type 2 immune cells have been shown to activate various inhibitory regulatory cells and growth factors that can decrease both the activity of immune effectors and the immune sensitivity of tumour cells. As is well known, immune sensitivity is linked to MHC class I chain-linked A/B stress molecules (MICA and MICB) on tumour cells, which are ligands for the principal activator of elimination receptor (NKG2D) on natural killer (NK) cells. Due to the discovery several years ago that Gemcitabine can increase the expression of MICA and MICB on tumour cells, its combination with an evidence-based immunomodulator is of increasing clinical interest. Materials and methods: This report presents the case of a patient with metastatic and inoperable ductal adenocarcinoma of the pancreas, who was treated with gemcitabine (1678 mg) and nab-paclitaxel (210 mg) every 1-8-15 days of the month, in eight cycles. This therapy was regularly combined with 45 mg / kg of Biobran /MGN-3 administered orally three times a week, which is a standardised rice bran arabinoxylan concentrate. Results: In a 56-year-old patient, an inoperable ductal adenocarcinoma (39x46 mm) in the caudal part of the pancreas with multiple liver metastases (10-30 mm) was established by CT scan and biopsy. The patient was in a near-terminal phase (he had lost 27 kg of weight and was in severe pain). Three months after the start of treatment, the CT scan showed remission of the pancreatic tumour (25x38 mm) and an average reduction of 3 to 10 mm in liver metastases. Seven months later, there was complete remission of the pancreatic tumour and a further 3-6 mm reduction in liver metastases. These remissions were also observed after 10 months. The patient no longer complained of anything and was able to work at 100%. Conclusion: The combination of gemcitabine with standardised, evidence-based immunomodulators (such as MGN-3) may open up new strategies in tumour therapy.


"ImunoBran MGN-3 (BioBran MGN-3)" Effect of reducing chemotherapy side effects in breast cancer patients.


Download the document HERE


ABSTRACT... Objective: The aim of the study was to evaluate the effect of ImunoBran in reducing chemotherapy-induced side effects in terms of fatigue, anorexia, vomiting and hair loss, as well as quality of life in terms of weight loss. Setting: Radiotherapy Department, Nishtar Hospital, Multan, Pakistan. Material and methods: Fifty (50) breast cancer patients were randomly divided into two groups. Group A patients received a dose of 3 grams of ImunoBran MGN-3 daily one week before and one week after chemotherapy. Patients in group B received chemotherapy alone. A total of six cycles of chemotherapy were administered. No vitamin supplements or dietary supplements were administered during this study. Chemotherapy-induced side effects (fatigue, anorexia, vomiting, hair loss) were assessed using a questionnaire sent to patients before the start of each cycle. Weight was checked before each cycle to assess weight gain or loss. White blood cells were monitored by a complete blood count just before and one week after chemotherapy. Results: Over six months, fifty (50) patients divided into 2 groups (25 patients group A and 25 patients group B) were recruited from the radiotherapy department of Nishtar Hospital, Multan, Pakistan. There was a significant reduction in fatigue and anorexia in group A patients. 20 (80%) patients in group A experienced an increase in their diet and no fatigue without any snacks or vitamin supplements. However, patients in group B requested snacks because of severe anorexia after chemotherapy, with the exception of 3 (12%) patients who did not use snacks or supplements. In group A, 15 (60%) patients did not require antiemetics, whereas in group B, all patients (100%) suffered from severe nausea during and after chemotherapy. Patients in group A experienced less hair loss (28%, or 7 patients) than those in group B (100%, or 25 patients). Conclusions: The study showed that by helping to optimise the immune system, ImunoBran MGN-3 can not only help to maximise treatment success, but also minimise treatment side effects and improve quality of life during treatment and recovery.



Synergistic apoptotic effect of rice bran arabinoxylan (ImunoBran/MGN-3/Biobran) and curcumin (turmeric) on the human multiple myeloma cell line U266 in vitro

Download the document HERE​

ABSTRACT: The present study was performed to investigate the synergistic apoptotic potential of arabinoxylan rice bran (MGN-3/Biobran) and curcumin (turmeric) on the human multiple myeloma (MM) cell line U266, in vitro. U266 cells were cultured with MGN-3 (50 or 100µg/ml) and curcumin (2.5-10µM) for 3 days. The effects of MGN-3 and curcumin on the growth and survival of U266 cells were determined by trypan blue, MTT assay, flow cytometry analysis of cancer cell cycle and apoptosis. Expression of the proapoptotic protein Bax and the antiapoptotic protein Bcl2 was determined by Western blot analysis. Treatment with MGN-3 alone or curcumin alone resulted in a dose-dependent inhibition of U266 cell proliferation. However, a synergistic effect was observed after treatment with both agents, which was maximised at 100µg/ml MGN-3 plus 10µM curcumin. This synergy was characterised by an 87% reduction in the number of cells and a 2.6-fold increase in the percentage of apoptotic U266 cells. Cell cycle analysis showed a 53% reduction in the percentage of cells in G0-G1 phase treated with MGN-3 and curcumin (from 36% to 17%). Analysis of the expression of the pro- and anti-apoptotic molecules Bax and Bcl-2 revealed synergistic effects of these agents, with the expression of Bcl-2 being reduced and that of Bax increased. The result is a cellular microenvironment favourable to apoptosis. We conclude that MGN-3 and curcumin act synergistically in inducing apoptosis in U266 cells. These data may serve as a basis for in vivo studies that could have therapeutic implications.


Home Products Research Distributors Contact Can synergistic activation of pattern recognition receptors by plant immunomodulators enhance the effect of oncology therapy? Case report of a patient with sarcoma of the uterus and ovary


​Download the document HERE

Background: A growing body of evidence supports the hypothesis that, like microbes, various plant extracts may also contain pathogen-associated molecular pattern (PAMP)-like structures that can activate type 1 cellular functions of the innate immune system. Given that they are important for tumour defence and that chemical production of PAMP structures is difficult to achieve, plant extracts standardised on the basis of their PAMP structures could hold promise for future tumour therapies. Method: The synergistic effect of two standardised plant immunomodulators was monitored by haemocytological measurement of peripheral Natural Killer (NK) cell levels. Suboptimal doses of istletoe lectins (ML) and Arabinoxylan in MGN-3 were compared using healthy volunteers. Results: 24 hours after a sub-optimal dose (15 mg/kg) of Arabinoxylan in MGN-3, a mean (+/-SEM) increase in NK levels was 46.4 (+/-36) % and 24 hours after a sub-optimal injection (0.45 ng/kg) of ML, an increase of 36 (+/-13) % was found. If these sub-optimal doses of arabinoxylan and ML were administered together, a highly significant increase (293 +/-41%) was established, indicating a significant synergy between the two (p<0.001). A patient with sarcoma of the uterus and ovary could not tolerate CYVADIC chemotherapy. After combination with ML and Arabinoxylan using optimal doses of 0.75 ng/kg and 45 mg/kg respectively, she received six cycles of CYVADIC and subsequently only immunotherapy. She remained tumour-free for the next five years. Conclusion: The combination of standardised plant extracts with PAMP-type structures seems to open up new prospects in supportive therapy for metastatic tumours. Further research is required.


Can a standardised, evidence-based plant immunomodulator (composed of rice bran arabinoxylan) synergistically enhance the effects of gemcitabine? Case study of a patient with ductal carcinoma of the pancreas. 

​Download the document HERE

Background: Pancreatic ductal carcinoma is the leading cause of cancer-related death. Gemcitabine combined with nab-Paclitaxel as a standard first-line treatment leads to an improvement in clinical parameters, but this is only transient. Immunological observations suggest that in the background of this rapid resistance, tumour-induced dysregulation of the immune balance may also play a role. Tumour-induced innate type 2 immune cells have been shown to activate various inhibitory regulatory cells and growth factors that can decrease both the activity of immune effectors and the immune sensitivity of tumour cells. As is well known, immune sensitivity is linked to MHC class I chain-linked A/B stress molecules (MICA and MICB) on tumour cells, which are ligands for the principal activator of elimination receptor (NKG2D) on natural killer (NK) cells. Due to the discovery several years ago that Gemcitabine can increase the expression of MICA and MICB on tumour cells, its combination with an evidence-based immunomodulator is of increasing clinical interest. Materials and methods: This report presents the case of a patient with metastatic and inoperable ductal adenocarcinoma of the pancreas, who was treated with gemcitabine (1678 mg) and nab-paclitaxel (210 mg) every 1-8-15 days of the month, in eight cycles. This therapy was regularly combined with 45 mg / kg of Biobran /MGN-3 administered orally three times a week, which is a standardised rice bran arabinoxylan concentrate. Results: In a 56-year-old patient, an inoperable ductal adenocarcinoma (39x46 mm) in the caudal part of the pancreas with multiple liver metastases (10-30 mm) was established by CT scan and biopsy. The patient was in a near-terminal phase (he had lost 27 kg of weight and was in severe pain). Three months after the start of treatment, the CT scan showed remission of the pancreatic tumour (25x38 mm) and an average reduction of 3 to 10 mm in liver metastases. Seven months later, there was complete remission of the pancreatic tumour and a further 3-6 mm reduction in liver metastases. These remissions were also observed after 10 months. The patient no longer complained of anything and was able to work at 100%. Conclusion: The combination of gemcitabine with standardised, evidence-based immunomodulators (such as MGN-3) may open up new strategies in tumour therapy.


More studies on viral infections such as HIV and hepatitis B and C 

New effects of a hydrolysed polysaccharide-based dietary supplement on immune, liver and kidney function in HIV-positive adults in a randomised, double-blind, placebo-controlled trial.

​Download the document HERE


Summary: The primary objective of the study was to evaluate the effects of a hydrolysed polysaccharide, rice bran arabinoxylan compound (RBAC), on immune, liver and kidney function in HIV-positive individuals. The intervention was conducted as part of a randomised, double-blind, placebo-controlled trial lasting six months. Forty-seven HIV þ participants on stable antiretroviral therapy were recruited and randomly assigned to one of two study conditions (n 1⁄4 22 RBAC and n 1⁄4 25 placebo) and consumed 3 grams/day of either compound for six months. Participants were assessed at baseline and 3 and 6 months later for CD4þ and CD8þ, liver enzymes and kidney function. No side effects were reported, and liver and kidney markers remained almost within normal limits. The percentage change in CD4þ count was similar in the placebo (þ2.2%) and RBAC (þ3.1%) groups after 6 months of follow-up. The percentage change in CD8þ count decreased significantly from baseline to 6 months in the RBAC group (-5.2%), while it increased in the placebo group (þ57.8%; p 1⁄4 0.04). The CD4þ/CD8þ ratio improved clinically in the RBAC arm from 0.95 (SD 1⁄40.62) at baseline to 1.07 (SD 1⁄40.11) at 6 months, whereas it decreased in the placebo arm from 0.96 (SD 1⁄40.80) at baseline to 0.72 (SD 1⁄40.59) at 6 months. Our results showed a statistically significant decrease in CD8þ counts and a clinically significant increase in the CD4þ/CD8þ ratio for the RBAC group compared with the placebo group. Thus, the results of this study suggest that the immunomodulatory and antisenescent activities of RBAC are promising for the HIV population.


The clinical effectiveness of BioBran in immunotherapy for patients with hepatitis B

​Download the document HERE

Abstract: Hepatitis B virus (HBV) infection is a serious global health problem with devastating consequences of chronic hepatitis, cirrhosis, and hepatocellular carcinoma. More efficacious treatments, mass immunization programs, and safe injection techniques are essential for eliminating HBV infection and reducing global HBV-related morbidity and mortality. Antiviral therapy has been the primary treatments to date. However, conventional treatment has undesirable side-effects and continuous treatment can lead to the development of resistance. In addition, antiviral medicines are costly, thousands of dollars per year, and are not widely available in many countries, especially in the developing world. BioBran is a food supplement that is combined with conventional treatment to improve the outcome of the disease. There were 3 cases of viral B hepatitis patients who have treated by the combination of conventional antiviral therapy and BioBran were described. In these cases, blood samples were taken to measure liver function and immunopotency, and the results were compared with changes in clinical and image condition. Improvements were noted in most of the cases. Finally, some remarks were provided to enhance the effectiveness of treatment progress.


Rice bran arabinoxylan (ImunoBran®) reduces viremia in patients with chronic HCV infection: randomised trial*.

​Download the document HERE

Objective: Current treatments for the hepatitis C virus (HCV) have serious side effects and are very expensive. There is a need to explore natural therapies that are effective against HCV, less toxic and more cost-effective. In the present study, 37 patients with chronic HCV were randomised to receive either pegylated interferon (PEG IFN) plus ribavirin (n = 21) or Biobran, an arabinoxylan derived from rice bran (1 g/day) (n = 16). We examined viremia, liver enzymes, serum interferon-γ (IFN-γ) levels and toxicity before and three months after treatment. Both groups showed a significant and similar reduction in viral load after three months of treatment compared with baseline viral load (P<0.05). In addition, Biobran treatment resulted in a significant increase in IFN-γ levels (P <0.001). Patients in the PEG IFN plus ribavirin arm experienced fever, anaemia, thrombocytopenia and severe fatigue. Patients in the Biobran group had no side effects and reported good health. We conclude that Biobran is a potential new therapeutic regimen that has a similar effect to the combination of PEG IFN and ribavirin and is safe and cost-effective in the treatment of chronic HCV. Our finding of Biobran's efficacy against HCV infection warrants further investigation in multiple clinical trials (clinical trial registration: NCT02690103).


New effects of a hydrolysed polysaccharide-based dietary supplement on immune, liver and kidney function in HIV-positive adults in a randomised, double-blind, placebo-controlled trial.

 Download the document HERE

Summary: The primary objective of the study was to evaluate the effects of a hydrolysed polysaccharide, rice bran arabinoxylan compound (RBAC), on immune, liver and kidney function in HIV-positive individuals. The intervention was conducted as part of a randomised, double-blind, placebo-controlled trial lasting six months. Forty-seven HIV þ participants on stable antiretroviral therapy were recruited and randomly assigned to one of two study conditions (n 1⁄4 22 RBAC and n 1⁄4 25 placebo) and consumed 3 grams/day of either compound for six months. Participants were assessed at baseline and 3 and 6 months later for CD4þ and CD8þ, liver enzymes and kidney function. No side effects were reported, and liver and kidney markers remained almost within normal limits. The percentage change in CD4þ count was similar in the placebo (þ2.2%) and RBAC (þ3.1%) groups after 6 months of follow-up. The percentage change in CD8þ count decreased significantly from baseline to 6 months in the RBAC group (-5.2%), while it increased in the placebo group (þ57.8%; p 1⁄4 0.04). The CD4þ/CD8þ ratio improved clinically in the RBAC arm from 0.95 (SD 1⁄40.62) at baseline to 1.07 (SD 1⁄40.11) at 6 months, whereas it decreased in the placebo arm from 0.96 (SD 1⁄40.80) at baseline to 0.72 (SD 1⁄40.59) at 6 months. Our results showed a statistically significant decrease in CD8þ counts and a clinically significant increase in the CD4þ/CD8þ ratio for the RBAC group compared with the placebo group. Thus, the results of this study suggest that the immunomodulatory and antisenescent activities of RBAC are promising for the HIV population.




Selection of studies on ImunoBran and bacterial and viral infections

ImunoBran/Biobran/MGN-3, a rice bran containing arabinoxylan, protects against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): An in vitro and in silico study

Download the document HERE 

Summary: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus 2019 (COVID-19), represents a serious threat to global public health for which there is currently no satisfactory treatment. This study examines the efficacy of ImunoBran/Biobran/MGN-3 against SARS-CoV-2. ImunoBran/Biobran is an arabinoxylan rice bran that has been shown to significantly inhibit related influenza virus in geriatric subjects. The anti-SARS-CoV-2 activity of ImunoBran/Biobran was assessed using MTT and plaque reduction assays, RT-PCR and ELISA techniques, and measurements of SARS-CoV-2-related gene expression and protein levels. In Vero E6 cells infected with SARS-CoV-2, ImunoBran/Biobran reduced the viral load by 91.9% at a dose of 100 µg/mL, reduced the number of viruses (PFU/mL) by 90.6% at 50 µg/mL, and exhibited a significant selectivity index (EC50/IC50) of 22.5. In addition, ImunoBran/Biobran at 10 µg/mL inhibited papain-like proteinase (PLpro) by 87% and ACE2 SARS-CoV-2 Sprotein RBD by 90.5%, and significantly suppressed SARS-CoV-2 gene expression, decreasing E and RdRp gene expression by 93% each at 50 µg/mL and inhibiting E protein by 91.3%. An in silico docking study was also performed to examine the protein-protein interaction (PPI) between SARS-CoV-2 RBD and DC-SIGN and between serine carboxypeptidase and the papain-like protease PLpro. Serine carboxypeptidase, an active ingredient in Biobran, was found to interfere with the binding of SARS-CoV-2 to its receptor DC-SIGN on Vero cells, preventing SARS-CoV-2 from entering the cell. It also interfered with the viral replication cycle by binding to PLpro. We conclude that ImunoBran/Biobran has potent antiviral activity against SARS-CoV-2 in vitro and suggest that ImunoBran/Biobran may be able to prevent SARS-CoV-2 infection. This warrants further investigation in clinical trials.


Dietary supplementation with ImunoBran/BioBran/MGN-3 increases innate resistance and reduces the incidence of influenza-like illness in the elderly : A randomised, double-blind, placebo-controlled pilot clinical trial

​Download the document HERE

Summary: Influenza-like illness (ILI) remains a major cause of serious mortality and morbidity in the elderly. Ageing is associated with a reduced ability to detect pathogens and to mount effective innate and adaptive immune responses, making it necessary to develop protective nutraceuticals. Biobran/MGN-3, an arabinoxylan derived from rice bran, has powerful anti-ageing and immunomodulatory effects, suggesting that it could be effective against ILI. The aim of the present study was to examine the effect of Biobran/MGN-3 on the incidence of OS, natural killer (NK) cell activity and the expressions of RIG-1 (retinoic acid inducible gene 1), MDA5 (melanoma differentiation-associated protein 5) and their downstream signalling genes ISG-15 (interferon-stimulated gene 15) and MX1 (interferon-inducible myxovirus (influenza) resistance 1). A double-blind, placebo-controlled clinical trial included eighty people over the age of 55, 40 men and 40 women, who received either placebo or Biobran/MGN-3 (500 mg/day) for 3 months during the known seasonality of ILI (peak incidence) in Egypt. The incidence of ILI was clinically confirmed according to WHO case definition criteria. Haematological, hepatic and renal parameters were assessed in all subjects, while NK and NKT (natural killer T) cell activity was assessed in six subjects randomly selected from each group by degranulation assay. The effect of Biobran/MGN-3 on RIG-1 and MDA5, as well as downstream ISG15 and MX1, was assessed in BEAS-2B lung epithelial cells using flow cytometry. The incidence rate and incidence density of OS in the Biobran/MGN-3 group were 5.0% and 0.57 cases per 1000 person-days respectively, compared with 22.5% and 2.95 cases per 1000 person-days in the placebo group. In addition, ingestion of Biobran/MGN-3 significantly increased NK activity compared with baseline and placebo. In addition, Biobran/MGN-3 significantly increased the expression levels of RIG-1, MDA5, ISG15 and MX1 in BEAS-2B human lung epithelial cell lines. No side effects were observed. Overall, Biobran/MGN-3 supplementation enhanced the innate immune response of the elderly by increasing NK activity associated with a reduced incidence of ILI. It also increased intracellular expression of RIG-1, MDA5, ISG15 and MX1 in lung epithelial tissue cultures. Biobran/MGN-3 could be a novel agent with prophylactic effects against a broad spectrum of respiratory viral infections, warranting further investigation.


ImunoBran/MGN-3/BIOBRAN enhances the generation of cytotoxic CD8+ T cells by regulating DEC-205 expression on dendritic cells

Download the document HERE

Objective: Rice bran arabinoxylan (MGN-3/Biobran) has been shown to be a potent biological response modifier (BRM) that activates different branches of the immune system, including dendritic cells (DCs), which stimulate CD4+ helper T cell responses. The present study explores the ability of MGN-3-activated dendritic cells to stimulate CD8+ T cells and examines the mechanisms underlying this effect. Human monocyte-derived DCs were treated with MGN-3 (20 and 40 µg/ml). The results indicate that MGN-3 treatment enabled DCs to stimulate CD8+ T cells expressing granzyme B in greater numbers. MGN-3 DCs stimulated by tumour lysate also increased tumour cell killing compared with DC-stimulated CD8+ T cells. This was associated with: i) increased DEC-205 expression in MGN-3-activated DCs in a dose-dependent manner; and ii) MGN-3 induced significant production of type III interferon, IL29, but not type I on and B IFNs. These results suggest that MGN-3 is a powerful natural adjuvant that effectively activates DCs and may therefore be useful for mounting an effective immune response against infections and cancer.



Activation of monocyte-derived human dendritic cells in vitro by the biological response modifier Arabinoxylan Rice Bran (ImunoBran/MGN-3/Biobran)

​Download the document HERE

Objective: Rice bran arabinoxylan (MGN-3/Biobran) is a powerful biological response modifier (BRM) that activates natural killer (NK) cells, T cells and monocytes. Currently, little is known about the effects of MGN-3 on dendritic cells (DCs), the cell type that links innate and adaptive immunity. We therefore examined the stimulatory effects of MGN-3 on dendritic cells. DCs derived from human monocytes were treated with MGN-3 at different concentrations (5-20 µg/ml) for 24 hours in vitro. DC activation was determined by assessing the expression of co-stimulation and maturation markers (CD40, CD80, CD83, CD86 and HLA-DR) by flow cytometry, and cytokine production by ELISA. The function of DCs was determined by assessing their ability to activate naive T cells. T cell activation was assessed by measuring cell proliferation and cytokine production. MGN-3 treatment, in a dose-dependent manner, resulted in: 1) increased surface expression of CD83 and CD86 on DCs; 2) increased production of pro-inflammatory and immunoregulatory cytokines (IL-lβ}, IL-6, IL-10, TNF-α, IL-12p40 and low levels of IL-12p70 and IL-2) by DCs; and 3) DC-induced proliferation of CD4T cells and their production of cytokines, IFN-7, IL-10, IL-17, stimulated by MGN-3. The results suggest that MGN-3 functions as a natural adjuvant for DC activation and can therefore be used in DC-based vaccine strategies against infections and cancer.





A selection of studies on ImunoBran and inflammatory conditions

Experience of ImunoBran/BioBran administration in patients with chronic rheumatism

​Download the document HERE


The functional food, arabinoxylan derivative of rice bran (BioBran), was administered over a long period to patients suffering from chronic rheumatism and receiving mainly steroid-based symptomatic treatments, in order to assess its complementary effect with representative treatments for rheumatism, such as steroids, analgesics and thermotherapy. Steroids are essential in the treatment of rheumatism, but it is advisable to keep the dose to a minimum, as they can cause undesirable effects. In recent years, numerous reports have been published on the functions of food ingredients, including superoxide scavenging and improved biophylaxis. This study assessed the effectiveness of BioBran, a functional food material. BioBran is thought to activate natural killer cells (NK cells) and inhibit inflammation. The author confirmed and reported that it relieved symptoms of cold in the elderly. The present study, in which 8 patients with chronic rheumatism received BioBran for 6 to 12 months, demonstrated improvements in symptoms and quality of life, suggesting its efficacy.


Therapeutic effects of Biobran, an arabinoxylan-modified rice bran, on the improvement of symptoms of diarrhoea-predominant or mixed irritable bowel syndrome: A pilot, randomised controlled study.

​Download the document HERE

Objective: Recently, it has been revealed that low-grade mucosal inflammation and/or immune imbalance in the lower digestive tract is one of the mechanisms involved in the generation of symptoms in patients with irritable bowel syndrome (IBS). Biobran, an arabinoxylan compound derived from rice bran, has been reported to have several biological actions such as anti-inflammatory and immunomodulatory effects. We therefore investigated the therapeutic effects of Biobran in patients with irritable bowel syndrome. Method. Forty patients with diarrhoea-predominant or mixed irritable bowel syndrome were randomly assigned to either a Biobran group for treatment with Biobran or a placebo group. Therapeutic efficacy and IBS symptoms were subjectively assessed by patients after 4 weeks of administration. Results. Global assessment was effective in 63.2% of the Biobran group and 30% of the placebo group (P < 0.05, Biobran group versus placebo group). The Biobran group showed a significant decrease in diarrhoea and constipation scores and CRP values. However, no significant change was observed in the placebo group. Conclusion: Administration of Biobran improved the symptoms of irritable bowel syndrome. It is likely that the anti-inflammatory and/or immunomodulatory effects of Biobran may be useful for patients suffering from irritable bowel syndrome.


Summary: Diabetes, chronic fatigue syndrome, irritable bowel syndrome,...

Health benefits and clinical applications of Shiitake mushroom enzyme-modified rice bran arabinoxylan - a narrative study

Download the document HERE

Summary: Rice bran arabinoxylan compound (RBAC) is derived from defatted rice bran hydrolysed with the mycelial enzyme of Lentinus edodes. It has been marketed as a functional food and nutraceutical with beneficial health properties. Some research has shown that this rice bran derivative is a powerful immunomodulator, which also has anti-inflammatory, antioxidant and anti-angiogenic properties. To date, research on RBAC has focused mainly on its immunomodulatory action and its application as a complementary cancer therapy. However, the clinical applications of RBAC may go beyond cancer therapy. This article is a narrative review of research on the potential benefits of RBAC for cancer and other health conditions, based on the available literature. Research on RBAC has shown its usefulness as a complementary treatment for cancer and human immunodeficiency virus infection. It can positively modulate serum glucose, lipid and protein metabolism in diabetic patients. In addition, RBAC has been shown to improve irritable bowel syndrome and protect against liver damage caused by hepatitis or non-alcoholic fatty liver. It can potentially reduce the symptoms of chronic fatigue syndrome and prevent the common cold. RBAC can be taken safely and has no known side effects at the usual dose of 2 to 3 g per day. Nevertheless, further research, both in basic studies and in human clinical trials, is needed to investigate the clinical applications, mechanisms and effects of RBAC.



Is any of this backed up by clinical research?

Unlike with most natural supplements, there has been very encouraging clinical research (see clinical research), including many human trials, carried out on ImunoBran® MGN-3 arabinoxylan, much of which have been published in peer-reviewed medical journals. This research has taken place at UCLA/DREW University in the United States, at some clinics and hospitals in Europe, and various universities and medical research institutions in Japan, including Chiba University, Kobe Women's College, Jichi Medical School, Nippon University, Kyushu University, Nagoya University, Kyoto University, Toyama Medical University and Kawasaki Medical University.

The main researcher on ImunoBran® MGN-3 has been Dr. Mamdooh Ghoneum, a professor at the Department of Immunology at Drew University of Medicine and Science in the United States. Dr. Ghoneum, now an internationally recognized authority on cancer immune therapy, received his Ph.D. at the University of Tokyo in radioimmunology and did his postdoctoral work at UCLA in immunology. Over the last 20 years he has been researching various substances that can enhance the immune system, but says that "ImunoBran® MGN-3 is the most powerful immune complex I have ever tested!" So impressed was he with the results that he has now devoted his entire research efforts to treatments with this compound.

Despite the fact that research into the immunological response to the arabinoxylan compound contained in ImunoBran® MGN-3 has been positive in the presence of a wide range of diseases, from cancer and diabetes to viral infections such as AIDS and hepatitis B and C, There is still a need for further in vivo clinical research, including randomised double-blind studies, to determine exactly to what extent the observed increase in immune response (particularly NK cell activity) influences cure and survival rates in the diseases mentioned.                                                                                                                                             

Is ImunoBran® MGN-3 toxic in any way or does it have any side effects?

No. ImunoBran® MGN-3 arabinoxylan compound is a natural product that has no adverse or toxic side-effects, confirmed by blood tests and examinations of liver and kidney function of people who have taken high amounts of the compound over several months. The only obvious contraindication is that, as an immunomodulator, able to boost weak immune systems, it should not be taken in conjunction with any medication specifically for suppressing the immune system.​

And, although mushroom enzymes are used in ImunoBran® MGN-3's manufacture, there is no mushroom content in the final product, which means that nearly all those with mushroom intolerances have been able to take it without an allergic reaction. This compound has also been authorized by the Japan Health Food and Nutrition Food Association, and has passed strict evaluation standards set under the guidance of the Ministry of Health and Welfare.

What dose of ImunoBran® MGN-3 should I take and when should I take it?

As the body does not build up a resistance to ImunoBran® MGN-3 over time, this food supplement can safely and effectively be taken over an extended period of time, and without the necessity of slowly increasing the dosage as with other immunomodulators.

Most research into ImunoBran® MGN-3 has been conducted using 30 to 45mg/kg/day in a divided dose with meals, with maintenance doses down to 15mg/kg/day. A dosage of at least 500mg a day should be taken for general health maintenance (unless potentised with yeast); for more serious immune support (such as in the case of arthritis, diabetes, hepatitis B, hepatitis C and other infections) the recommended dosage should be 1000mg a day; and for serious conditions where the immune system is severely compromised (such as with cancer or AIDS) 3g per day is recommended for 2 month and then 1g per day thereafter.

ImunoBran® MGN-3 should always be taken after food (ideally, 20-30 minutes after) and larger daily intakes should be divided into three portions and taken with breakfast, lunch and dinner. If the person taking the compound is very ill, they can stay on the 3g per day intake for an extended period.

Apart from the case of general health maintenance, we always recommend that your doctor be informed that you are taking this supplement, so that he or she can integrate it into your treatment program. intake for an extended period.


ImunoBran ® MGN-3 has been a dietary supplement in Europe, the United States and Japan for more than 30 years.